CEL-SCI Corporation  

(Public, NYSEMKT:CVM)   Watch this stock  
Find more results for CVM
-0.010 (-2.03%)
Nov 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.47 - 0.49
52 week 0.46 - 1.23
Open 0.49
Vol / Avg. 391,434.00/795,009.00
Mkt cap 53.19M
P/E     -
Div/yield     -
EPS -0.42
Shares 112.71M
Beta 0.17
Inst. own 5%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1137.95% -10364.83%
Operating margin -2271.92% -10443.56%
EBITD margin - -10290.47%
Return on average assets -103.82% -182.02%
Return on average equity -832.16% -332.30%
Employees 43 -
CDP Score - -


Suite 802, 8229 Boone Boulevard
VIENNA, VA 22182
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CEL-SCI Corporation is a biotechnology company. The Company is engaged in the research and development of drugs and vaccines. The Company researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Company's product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine. The Company's lead investigational therapy Multikine is in the Phase III clinical trial against head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration. LEAPS is the Company's pre-clinical technology.

Officers and directors

Maximilian D de Clara President, Director
Age: 85
Bio & Compensation  - Reuters
Geert R. Kersten Esq. Chief Executive Officer, Treasurer, Director
Age: 56
Bio & Compensation  - Reuters
Patricia B Prichep Senior Vice President - Operations, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
John Cipriano Senior Vice President - Regulatory Affairs
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel H Zimmerman Ph.D. Senior Vice President - Research, Cellular Immunology
Age: 73
Bio & Compensation  - Reuters
Eyal Talor Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Alexander G. Esterhazy Independent Director
Age: 73
Bio & Compensation  - Reuters
Peter R. Young Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters